To overcome known limitations of the use of CAR T cell therapy for glioma, such as antigen escape and the need for increased T cell persistence and potency, in the current manuscript, we tested a novel combination therapeutic approach with the Wnt/CBP/β-catenin antagonist ICG-001 to enhance the expression of genes involved in antigen presentation and the adaptive immune response. This evidence concerns the gene CREBBP and glioma.